metformin + repaglinide

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
84
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Diabetes

Conditions

Diabetes, Diabetes Mellitus, Type 2

Trial Timeline

Mar 6, 2002 โ†’ Oct 21, 2004

About metformin + repaglinide

metformin + repaglinide is a approved stage product being developed by Novo Nordisk for Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT01465152. Target conditions include Diabetes, Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01465152ApprovedCompleted